Hong Kong MDACS Expedited Approval Scheme for Medical Device Listing Applications

Quick answer

What is the Hong Kong MDACS expedited approval scheme for medical device listing?

Hong Kong's Medical Device Administrative Control System (MDACS), administered by the Medical Device Division (MDD) of the Department of Health, offers an Expedited Approval Scheme for Medical Device Listing Applications that streamlines review when strict eligibility criteria are met. The scheme covers Class II, III, and IV general medical devices (GMD) and, from 26 July 2024, Class B, C, and D in vitro diagnostic medical devices (IVDMD). To qualify, the applicant must be an existing Local Responsible Person (LRP) with a valid LRP listing number; the device must have no reported deaths or serious injuries and no active recalls, field safety corrective actions (FSCA), or adverse events (locally and worldwide); and all devices in the application must hold two or more valid, independent marketing approvals from jurisdictions listed in Section D002 of GN-02 or GN-06. Participation is opt-in by default — applicants tick the opt-out checkbox only if they do not want expedited processing. During review, the applicant must respond to MDD issues within two (2) weeks. Applications are filed through MDIS (Medical Device Information System). This scheme is not the Undesirable Medical Advertisements Ordinance (UMAO, Cap. 231), which governs advertising — not listing speed.

Who this applies to

This guide applies to:

• Local Responsible Persons (LRPs) with an existing, valid LRP listing number who submit MDACS listing applications on behalf of overseas manufacturers
• Regulatory affairs teams preparing Class II, III, or IV GMD or Class B, C, or D IVDMD listing dossiers under GN-02 or GN-06
• Sponsors whose devices already hold marketing approvals in two or more of MDD's recognised reference jurisdictions (NMPA, FDA, EU, Health Canada, MHLW, TGA, MFDS, HSA)
• Quality and vigilance leads responsible for confirming that post-market safety data support expedited eligibility

The scheme does not apply to Class I GMD or Class A IVDMD listing routes outside this scope, nor to applicants who are not yet registered as an LRP. It also does not replace the full MDACS technical dossier — expedited processing assumes a complete submission per GN-02 (GMD) or GN-06 (IVDMD), including D002 reference approvals, QMS certificates, labelling, and Essential Principles evidence.

Expedited scheme vs UMAO (Cap. 231): do not confuse these

Search traffic for "UMAO" and "expedited market access" in Hong Kong often conflates two unrelated MDACS topics. They operate under different legal bases and solve different problems:

If your query is about how quickly MDD can list a device, you need the Expedited Approval Scheme. If your query is about whether a promotional claim or advertisement complies with Hong Kong law, you need UMAO guidance. MDD administers MDACS listing; UMAO enforcement sits in a separate advertising-compliance framework. Cross-check both when launching a product in Hong Kong, but do not treat expedited listing as an advertising exemption.

What the Expedited Approval Scheme does

MDD introduced the Expedited Approval Scheme to streamline application and approval of qualifying listing applications. When all scheme criteria are satisfied, MDD reviews the dossier using an expedited approach rather than the standard 12-week ordinary track (GN-02 §5.3.1 still applies as the baseline timeframe reference for complete submissions).

Key programme rules from MDD's Notes for the Expedited Approval Scheme (ExpSch-Notes-E, October 2025):

• Scope: Class II/III/IV GMD listing applications; Class B/C/D IVDMD added effective 26 July 2024 (MDACS Activities announcement ID 2327)
• Safety gate: Worldwide and local vigilance data must be clean (no deaths/serious injury; no active recalls/FSCA/adverse events)
• Reference-approval gate: Two or more independent marketing approvals from recognised jurisdictions
• Applicant gate: Existing LRP with valid LRP listing number only
• Response duty: Applicant responds to MDD issues within two weeks of notice
• Fallback: If criteria are not met or issues are not addressed satisfactorily by the specified date, MDD may process the file as an ordinary application (ExpSch Notes §7)
• Amendments: MDD reserves the right to change scheme terms; check mdd.gov.hk for updates

After trial phases, MDD regularised the scheme for Class II/III/IV GMD from 4 January 2022 (MDACS Activities ID 2204), with details reflected in application form MD-C2&3&4 2022 Edition.

Four eligibility criteria (GN-02 / GN-06 Section E002)

Section E002 of GN-02 (GMD, form MD101) and GN-06 (IVDMD, form MD102) states that listing will be processed under the Expedited Approval Scheme only if all four criteria are satisfied:

Independent marketing approval means the approval is not dependent on another jurisdiction's approval status. The applicant must submit the full set of marketing approval documents — licences, certificates, approval letters, declarations of conformity, and related supporting papers — to demonstrate validity and independence (ExpSch Notes §4).

LRP scope requirement: Before applying, the applicant must ensure the device falls within the existing scope of documented procedures established by the LRP and recognised by MDD (ExpSch Notes §6). An LRP cannot expedite-list a device outside its approved LRP scope.

Hospital Authority procurement (optional E002 fields): If, to the applicant's knowledge, the device was procured by the Hospital Authority within the past 12 months, GN-02/GN-06 E002 requires purchase order number, order date, and supplier name in the designated fields. This does not replace the four core criteria but supports MDD's assessment.

Recognised reference jurisdictions for expedited listing

Under the scheme, MDD recognises marketing approval documents from the following agencies when the risk classification is appropriate (ExpSch Notes §3). These align with D002 reference jurisdictions in GN-02 and GN-06:

You need at least two different jurisdictions — not two documents from the same country. A single FDA 510(k) plus a single EU MDR certificate satisfies criterion (iv) if both cover all models in the Hong Kong application and are independent. For D002 document specifics per jurisdiction, see the companion article on the MDACS reference country pathway (hkg-mdacs-reference-country-marketing-approval-pathway).

Default opt-in and how to opt out

GN-02 and GN-06 E002 implement a default opt-in design:

Participation in the Expedited Approval Scheme is initiated by default to facilitate a streamlined review. The checkbox should be selected only if there is an intention to OPT OUT from the scheme.

Practical implications:

• Leave the opt-out checkbox blank if you want expedited processing and meet all four criteria
• Select the opt-out checkbox only when you intentionally want ordinary processing — for example, if vigilance data is borderline, you lack two independent approvals, or your team cannot guarantee a two-week response window
• Declaring expedited eligibility inaccurately risks reclassification to ordinary processing mid-review if MDD finds unaddressed issues (ExpSch Notes §7)

Expedited participation is not a separate MDIS form — it is declared in E002 of MD101 (GMD) or MD102 (IVDMD) within the standard listing application.

Two-week response timeline and review expectations

ExpSch Notes §2 requires the applicant to respond to any issues within two (2) weeks after receiving notice from MDD. This is shorter than the general GN-02 §5.3.1 expectation that applicants supply requested supporting information within two weeks upon request during ordinary vetting — expedited files face stricter calendar discipline.

Operational tips:

1. Pre-assign a response owner on the LRP team before MDIS submission
2. Monitor MDIS messages and email daily during active review
3. Prepare vigilance and approval certificates in advance so deficiency responses do not require weeks of sponsor retrieval
4. Miss the two-week window → MDD may close or downgrade the application to ordinary processing

GN-02 §5.3.1 notes that failure to provide requested information within the stipulated timeframe can result in closure of the application. Treat the expedited two-week rule as a hard operational SLA.

GMD vs IVDMD scope and the 26 July 2024 extension

On 26 July 2024, MDD announced that the Expedited Approval Scheme scope extends to Class B/C/D IVDMD listing applications. MDD simultaneously pointed applicants to updated GN-06 and ExpSch Notes. IVD sponsors use the same four E002 criteria and the same default opt-in mechanism as GMD sponsors, but must follow TR-005 labelling rules, TR-006 classification, and GN-06 D002 IVD-specific reference document requirements (IVDR/IVDD transition rules differ from GMD).

Class A IVDMD and Class I GMD remain outside this expedited listing scope.

Step-by-step MDIS submission workflow

Follow these steps when preparing an expedited listing application:

1. Confirm device class under TR-003 (GMD) or TR-006 (IVDMD) and select GN-02/MD101 or GN-06/MD102 accordingly.
2. Verify LRP status — valid LRP listing number and device within LRP's MDD-recognised scope of documented procedures.
3. Run the eligibility decision tree:
   • Deaths/serious injuries? → if yes, opt out or do not apply under scheme
   • Active recalls/FSCA/AEs? → if yes, opt out
   • Fewer than two independent D002 approvals covering all models? → opt out
   • All clear? → proceed expedited (default)
4. Assemble the full MDACS dossier — Part C technical documentation, D001/D002 conformity route, QMS certificate (ISO 13485 or accepted equivalent), labelling per TR-004/TR-005, Essential Principles checklist, clinical or performance evaluation.
5. Complete E002 — confirm all four criteria; leave opt-out unchecked unless opting out; complete Hospital Authority fields if applicable.
6. Log in to MDIS via the MDIS information page (portal: mdis.mdd.gov.hk).
7. Submit electronically and retain the MDIS acknowledgement reference.
8. Respond within two weeks to any MDD deficiency or query notice; upload corrections through MDIS.
9. If MDD downgrades to ordinary processing, continue cooperating under standard 12-week vetting rules (GN-02 §5.3.1).

Key documents and what they must contain

Expedited processing does not waive any Part C document class required for ordinary listing.

Checklist

Use this checklist before ticking E002 expedited participation (opt-in by default):

• Device is Class II, III, or IV GMD or Class B, C, or D IVDMD
• Applicant is an existing LRP with valid LRP listing number
• Device is within LRP's MDD-recognised scope of documented procedures
• No deaths or serious injuries reported locally or worldwide for the device
• No active recalls, FSCA, or adverse events locally or worldwide
• Two or more independent D002 marketing approvals cover all models in the application
• Full MDACS dossier prepared per GN-02 or GN-06 (not a reduced package)
• Opt-out checkbox left blank (unless intentionally choosing ordinary processing)
• Team can respond to MDD within two weeks of any notice
• MDIS login active; submission route confirmed at mdis.mdd.gov.hk
• Not confusing this process with UMAO Cap. 231 advertising rules

Common pitfalls

1. Searching "UMAO" for expedited listing — UMAO is Cap. 231 advertising law; it does not accelerate MDACS listing. Use this expedited scheme article instead.
2. Counting two certificates from one country — criterion (iv) requires two or more jurisdictions, not two documents from FDA alone.
3. Dependent approvals — a licence that relies on another country's approval does not count as independent (ExpSch Notes §4).
4. New LRP without listing number — only existing LRPs participate; register the LRP first through MDACS before expedited device listing.
5. Ignoring worldwide vigilance — E002 (ii) and (iii) cover local and worldwide data; US FDA recall or EMA FSCA can disqualify expedited treatment even if Hong Kong has no local reports.
6. Missing the two-week response window — delays invite downgrade to ordinary processing or application closure.
7. Assuming expedited means reduced dossier — MDD still expects the full GN-02/GN-06 submission; only the review track changes.
8. IVD applications before 26 July 2024 rules — confirm the current GN-06 E002 text applies; IVDMD was added to scheme scope on that date.

FAQ

What is the MDACS expedited approval scheme?

It is an MDD programme that streamlines listing review for Class II–IV GMD and Class B–D IVDMD when the applicant meets four E002 criteria: valid existing LRP, clean vigilance history, no active recalls/FSCA/adverse events, and two or more independent D002 marketing approvals. Applications go through MDIS; participation is default opt-in.

Who qualifies for expedited listing in Hong Kong?

Only an existing Local Responsible Person with a valid LRP listing number may participate. The device must have no reported deaths or serious injuries and no active recalls, FSCA, or adverse events (local and worldwide), and must hold at least two independent marketing approvals from MDD's recognised D002 jurisdictions covering all models in the application.

How many foreign approvals are needed for expedited MDACS listing?

Two or more valid, independent marketing approvals from separate recognised jurisdictions listed in GN-02/GN-06 D002 — for example FDA plus EU, or TGA plus Health Canada. They must cover all device models in the Hong Kong application and must not be dependent on each other.

Does the expedited scheme apply to IVD devices?

Yes, from 26 July 2024. MDD extended the Expedited Approval Scheme to Class B, C, and D IVDMD listing applications. Use GN-06, form MD102, and the same E002 criteria and default opt-in rules as GMD. Class A IVDMD is outside this scope.

What is the difference between UMAO and the expedited approval scheme?

UMAO (Cap. 231) is the Undesirable Medical Advertisements Ordinance — it regulates medical advertising, not listing timelines. The Expedited Approval Scheme is an MDACS listing review programme administered by MDD for eligible Class II–IV GMD and Class B–D IVDMD applications. They are separate topics.

Is participation mandatory under the expedited scheme?

No. Participation is initiated by default to streamline review, but you opt out by selecting the E002 checkbox when you do not want expedited processing or cannot meet the criteria. If criteria fail mid-review, MDD may treat the file as an ordinary application.

How fast must I respond to MDD during expedited review?

The applicant must respond to MDD issues within two (2) weeks after receiving notice (ExpSch Notes §2). Missing this deadline can result in downgrade to ordinary processing or application closure under GN-02 §5.3.1.

What happens if my device no longer meets expedited criteria during review?

MDD reserves the right to process the application as an ordinary application if issues are not effectively addressed by the specified date or if any scheme criterion is not satisfied (ExpSch Notes §7). Disputes on scheme decisions are final per MDD (ExpSch Notes §9).

Official sources

• MDD — Notes for the Expedited Approval Scheme for Medical Device Listing Applications (PDF)
• MDD — GN-02: Guidance Notes for Listing Class II/III/IV General Medical Devices (PDF)
• MDD — GN-06: Guidance Notes for Listing Class B/C/D In Vitro Diagnostic Medical Devices (PDF)
• MDD — MDACS Activities: IVDMD scope extension, 26 July 2024 (ID 2327)
• MDD — MDACS Activities: GMD scheme regularisation, 4 January 2022 (ID 2204)
• MDD — Medical Device Information System (MDIS) — information page